İleri Parkinson Hastalığında PEG-J Yerleştirmesi için Propofol İnfüzyonu ile Hedef Kontrollü Sedasyon: Güvenlik ve Fizibilite Üzerine Prospektif Gözlemsel Bir Çalışma.

Araştırma özeti

Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by

IntroductionThe management of sedation during percutaneous endoscopic gastrojejunostomy (PEG-J) placement in patients with advanced Parkinson's disease (PD) is challenging due to the complex interactions between PD treatment, anesthetic agents, and the disease's motor and non-motor symptoms. This study evaluates the effectiveness and safety of a target-controlled infusion (TCI) propofol protocol in the context of PEG-J placement in advanced PD patients.Materials and methodsThis prospective study included 169 patients diagnosed with advanced Parkinson's disease (Hoehn and Yahr stages 4 and 5) who underwent PEG-J placement at Târgu Mureș County Emergency Clinical Hospital, Romania. Sedation was induced and maintained using TCI propofol, with additional benzodiazepines and short-acting opioids, while muscle relaxants were not used. Procedural success rates and adverse outcomes were assessed for 30 days post-procedure.ResultsThe sedation protocol demonstrated a high procedural success rate. No deaths were reported within 30 days post-procedure.ConclusionThis study highlights the feasibility and clinical applicability of a TCI propofol protocol for PEG-J placement in patients with advanced PD (stages 4 and 5). While no deaths were recorded within the 30-day follow-up, the sample size is insufficient to draw definitive conclusions regarding long-term safety.

İlgili konular